April 9, 2021
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines.
Today they announced that a late-breaking abstract featuring new data in patients with hidradenitis suppurativa (HS) from its non-interventional study of patients with HS or atopic dermatitis (AD) has been selected for presentation at the Society for Investigative Dermatology (SID) 2021 Annual Meeting, being held virtually May 3-8, 2021.
The non-interventional study is evaluating expression of IRAK4 and other mediators of inflammation in the skin and blood of patients with HS or AD and the ex vivo effect of the IRAK4 degrader KT-474.
Abstract Presentation Details:
- Abstract: LB819
- Title: Multiple mediators of inflammation correlate with IRAK4 expression in the skin of hidradenitis suppurativa patients and are blocked by the IRAK4 protein degrader KT-474 in TLR-activated monocytes
- Session: Translational Studies
- Session Time: 2:30 PM-4:00 PM ET on Thursday, May 6th, 2021
- Presenter: Afsaneh Alavi, MD, Mayo Clinic (Principal Investigator)
The presentation will be available on-demand from May 3-31, 2021, and also will be available for download here.
